Last $6.00 USD
Change Today -0.22 / -3.54%
Volume 33.5K
ATNM On Other Exchanges
As of 5:15 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

actinium pharmaceuticals inc (ATNM) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/3/14 - $15.00
52 Week Low
01/13/14 - $4.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

actinium pharmaceuticals inc (ATNM) Related Businessweek News

No Related Businessweek News Found

actinium pharmaceuticals inc (ATNM) Details

Actinium Pharmaceuticals, Inc., a biotechnology company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform. Its products include Bismab-A for acute myeloid leukemia; Actimab-A, an antibody-drug construct that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia; and Iomab-B, an antibody-drug construct used in myeloconditioning for hematopoietic stem cells transplantation in various indications. The company was formerly known as Cactus Ventures, Inc. and changed its name to Actinium Pharmaceuticals, Inc. in April 2013. Actinium Pharmaceuticals, Inc. was founded in 2000 and is based in New York, New York.

6 Employees
Last Reported Date: 03/19/14
Founded in 2000

actinium pharmaceuticals inc (ATNM) Top Compensated Officers

Chief Executive Officer, President, Interim C...
Total Annual Compensation: $112.1K
Chief Operating Officer and Chief Medical Off...
Total Annual Compensation: $295.5K
Compensation as of Fiscal Year 2013.

actinium pharmaceuticals inc (ATNM) Key Developments

Actinium Receives Orphan-Drug Designation from FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

Actinium Pharmaceuticals, Inc. announced that the US Food and Drug Administration (FDA) has granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60. Actimab-A is currently in a multicenter Phase 1/2 trial clinical trial.

Actinium Pharmaceuticals, Inc. Presents at LD Micro Conference, Dec-03-2014 03:30 PM

Actinium Pharmaceuticals, Inc. Presents at LD Micro Conference, Dec-03-2014 03:30 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States. Speakers: Sandesh C. Seth, Executive Chairman and Member of Compensation Committee.

Actinium Pharmaceuticals, Inc., Annual General Meeting, Dec 22, 2014

Actinium Pharmaceuticals, Inc., Annual General Meeting, Dec 22, 2014., at 09:30 US Eastern Standard Time. Location: Sheraton Mahwah Hotel, 1. Agenda: To consider and elect David Nicholson and Richard Steinhart as class i directors to serve for a three-year term that expires at the 2017 annual meeting of stockholders, or until his successor is elected and qualified or until his earlier resignation or removal; to consider the ratify the appointment of GBH CPAs, pc as our independent registered public accounting firm; to consider the approve an amendment to our certificate of incorporation to increase the number of shares the corporation is authorized to issue to 375,000,000 shares, of which 300,000,000 shares of common stock, par value $0.001 per share, and 75,000,000 shares of preferred stock, par value $0.001 per share, shall be authorized; to consider the approve an amendment to our certificate of incorporation to remove the board size and update the classified board provisions of our charter; and to consider the and act upon any other business as may properly come before the annual meeting or any adjournments thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATNM:US $6.00 USD -0.22

ATNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ATNM.
View Industry Companies

Industry Analysis


Industry Average

Valuation ATNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 75.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTINIUM PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at